Human Papillomavirus vaccine
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cervical High Grade Squamous Intraepithelial Lesion
Conditions
Cervical High Grade Squamous Intraepithelial Lesion
Trial Timeline
Sep 2, 2014 → Mar 1, 2018
NCT ID
NCT01928225About Human Papillomavirus vaccine
Human Papillomavirus vaccine is a phase 2 stage product being developed by Merck for Cervical High Grade Squamous Intraepithelial Lesion. The current trial status is completed. This product is registered under clinical trial identifier NCT01928225. Target conditions include Cervical High Grade Squamous Intraepithelial Lesion.
What happened to similar drugs?
8 of 20 similar drugs in Cervical High Grade Squamous Intraepithelial Lesion were approved
Approved (8) Terminated (0) Active (12)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01928225 | Phase 2 | Completed |
| NCT00767897 | Pre-clinical | Completed |
| NCT01034358 | Approved | Completed |
Competing Products
20 competing products in Cervical High Grade Squamous Intraepithelial Lesion